TL;DR
This study investigates the prevalence and clinicopathological associations of 10 key genes in 884 non-small cell lung cancer (NSCLC) patients in eastern China using next-generation sequencing (NGS). It highlights that most patients harbor at least one genetic alteration, with EGFR being the most common, and identifies unique patterns for various gene alterations, including rare synchronous mutations.
What Problem Does This Paper Address?
Lung cancer, particularly non-small cell lung cancer (NSCLC), is a major global health concern. Advances in understanding the molecular underpinnings of NSCLC have led to the development of targeted therapies that can significantly improve patient outcomes. However, the landscape of genetic alterations in NSCLC is complex and can vary geographically. While certain mutations like EGFR are well-studied, a comprehensive understanding of the frequency and co-occurrence of multiple targetable gene alterations, and their correlation with patient characteristics, is crucial for personalized treatment strategies. This paper aims to address this by providing a detailed analysis of 10 key genes in a large cohort of NSCLC patients from eastern China, filling a gap in regional genetic profiling.
Methods
The study employed next-generation sequencing (NGS) to analyze the status of 10 targeted genes (EGFR, HER2, BRAF, KRAS, ALK, MET, NRAS, PIK3CA, RET, and ROS1) in tumor samples from 884 NSCLC patients. Genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue. The NGS library preparation and sequencing were performed using a specific kit and an Illumina MiniSeq system. Data analysis involved identifying alterations using tools like BWA, Freebayes, and Annoval, with a minimum sequencing depth of 500x and a single nucleotide variation cutoff of 1%. Standard statistical methods, including Chi-square tests and Fisher's exact tests, were used to analyze the association between gene alterations and clinicopathological features, with SPSS 24.0 software.
Datasets
The study utilized a dataset of 884 NSCLC patients from the Affiliated Hospital of Qingdao University. These patients underwent surgical resection, bronchoscopy biopsy, or percutaneous transthoracic biopsy between June 2017 and September 2018. The dataset included detailed clinicopathological information such as age, gender, smoking history, tumor location, metastasis, TNM stage, and serum tumor marker levels. No new benchmark datasets were introduced.
Key Insights and Ideas
- High Prevalence of Genetic Alterations: The finding that a substantial majority (77.4%) of NSCLC patients harbor at least one genetic alteration underscores the molecular heterogeneity of the disease and the potential for targeted therapy.
- EGFR Dominance, but Diverse Landscape: While EGFR mutations are the most frequent, the study highlights the significant presence of other actionable mutations like KRAS, HER2, PIK3CA, and ALK, emphasizing the need for broad genetic profiling.
- Unique Associations with Clinicopathological Features: Each gene alteration demonstrated distinct associations with patient characteristics (e.g., EGFR with females and non-smokers, KRAS with males and smokers), providing valuable insights for risk stratification and potential treatment selection.
- Rare Synchronous Mutations: The identification of several rare synchronous mutations (co-alterations) is a critical finding. These combinations, such as EGFR/PIK3CA and EGFR/HER2, suggest complex molecular interactions and may influence treatment response, warranting further investigation.
- Histological Subtype Significance: Certain alterations, like ALK and ROS1 rearrangements, were found to be more frequent in specific histological subtypes (e.g., micropapillary structures), reinforcing the importance of integrating histological and molecular information.
Key Results
- Overall Alteration Rate: 684 out of 884 patients (77.4%) had at least one gene alteration.
- Most Common Mutations: EGFR (57.7%), KRAS (10.3%), HER2 (4.3%), PIK3CA (3.6%), and ALK (2.4%) were the most frequent alterations.
- Synchronous Mutations: 33 patients (3.7%) had more than one driver gene alteration. EGFR/PIK3CA was the most common co-alteration (2.1%).
- EGFR Associations: EGFR mutations were significantly more frequent in females, non-smokers, patients with normal serum tumor markers, those without lymph node metastasis, and in early-stage disease.
- KRAS Associations: KRAS mutations were more common in men, smokers, and patients with higher serum tumor markers.
- ALK/ROS1 Associations: ALK and ROS1 rearrangements were more frequent in adenocarcinomas with a mucus-producing component and micropapillary structures.
- BRAF Associations: BRAF mutations were significantly associated with advanced disease and micropapillary structures.
- PIK3CA Associations: PIK3CA mutations were more likely in elderly patients.
Limitations and Future Work
The authors acknowledge that the number of patients with rare mutations (e.g., MET, RET, NRAS) was too low for robust statistical analysis. Future work could focus on expanding the cohort to include these rare alterations and further investigate the clinical significance and therapeutic implications of synchronous mutations, particularly in guiding treatment decisions for NSCLC patients. The study also suggests that pathologists should meticulously report all histological components, even non-predominant ones, as they may be associated with specific gene alterations.
Summary updated